Securities Code: 300110
Securities Abbreviation: Huaren Pharmaceutical
Announcement No.: 2026-031
Huaren Pharmaceutical Co., Ltd.
Announcement on Receiving the Decision of Qingdao Regulatory Bureau of CSRC to Order Rectification
The Company and all members of its board of directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.
Huaren Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") received the "Decision on Ordering Huaren Pharmaceutical Co., Ltd. to Rectify Regulatory Measures" (No. [2026] 26) (hereinafter referred to as the "Decision") issued by the Qingdao Regulatory Bureau of the China Securities Regulatory Commission (hereinafter referred to as the "Qingdao Regulatory Bureau") on July 31, 2026. The specific situation is hereby announced as follows:
I. Main Contents of the "Decision"
"Huaren Pharmaceutical Co., Ltd.:
Upon investigation, your company has the following problems:
- The internal control mechanism for trade business is not sound, internal systems are not fully implemented, contracts are not fully performed or inadequately monitored, which does not comply with Article 36 of the "Basic Norms for Enterprise Internal Control" (Cai Kuai [2008] No. 7), Article 94 of the "Code of Corporate Governance for Listed Companies" (CSRC Announcement [2018] No. 29), Article 3, Paragraph 4, Article 4, Paragraph 1, Article 19, Paragraph 1, Article 20, Paragraph 1, Article 21, Paragraph 1 of the "Application Guidelines for Enterprise Internal Control No. 6 - Capital Activities" (Cai Kuai [2010] No. 11), Article 5, Paragraphs 2 and 3 of the "Application Guidelines for Enterprise Internal Control No. 9 - Sales Business" (Cai Kuai [2010] No. 11), and Article 8, Paragraph 1 of the "Application Guidelines for Enterprise Internal Control No. 16 - Contract Management" (Cai Kuai [2010] No. 11).